Drug Trial Radar · NCT04637828
A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection
Last checked: Nov 19, 2026Latest source record: Jul 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
178
Planned (sponsor's estimate)
Start
Nov 18, 2020
Primary completion
Jul 30, 2021
Study completion Dec 30, 2021
Sponsor
- Lead sponsor
- Genoscience PharmaIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, controlled, randomized phase 2 study designed to evaluate the safety and efficacy profile of GNS561 in patients with COVID-19.
Conditions
- COVID-19
Interventions
GNS561Drug
study drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- number and proportion of participants, per randomized group, with a loss of one or two grades of National Early Warning Score (NEWS2) score at day-7 compared to baselineTime frame: 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Genoscience Pharma
Marseille, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.